

Prostate Cancer: A worldwide approach

Monday, July 11th, 2022

18:30 - 19:00 GMT-4	Who, when and how to biopsy. Current state of the art on prostate cancer detection	Mark Emberton, MD (UK)
19:00 - 19:30 GMT-4	What is what... An update on prostate cancer pathology	Andrés Matoso, MD (USA)
19:30 - 20:00 GMT-4	MRI, microultrasound and everything you need to know about active surveillance on 2022	Laurence Klotz, MD (Canadá)
20:00 - 21:00 GMT-4	Clinical case diagnosis	

Tuesday, July 12th, 2022

18:30 - 19:00 GMT-4	Predicting prostate cancer behavior, are we there yet ? Biomarkers and genomics	Levin Martínez, MD (Uruguay)
19:00 - 19:30 GMT-4	Current role of focal therapy in the shifting paradigm of prostate cancer treatment	Rafael Sánchez-Salas, MD (Canadá)
19:30 - 20:00 GMT-4	Bayer symposium	
20:00 - 21:00 GMT-4	Clinical case localized disease	

Wednesday, July 13th, 2022

18:30 - 19:00 GMT-4	State of the art robotic radical prostatectomy, decreasing collateral damage	Rafael Coelho, MD (Brazil)
19:00 - 19:30 GMT-4	High risk patient, the surgeons view	Stephen Boorjian, MD (USA)
19:30 - 20:00 GMT-4	High risk patient, the radiotherapist view	Alejandro Berlín, MD (Canadá)
20:00 - 21:00 GMT-4	Clinical case high risk localized disease	

Thursday, July 14th, 2022

18:30 - 19:00 GMT-4	Clinical N1, pathological N1 and all you need to know about locally advanced disease	Karim Touijer, MD (USA)
19:00 - 19:30 GMT-4	Biochemical recurrence, salvage radiotherapy and MDT	Brian Chapin, MD (USA)
19:30 - 20:00 GMT-4	Janssen Symposium	
20:00 - 21:00 GMT-4	Prostamets: predictor test for metastatic disease	Javier Cerda, PhD (Chile)

Friday, July 15th, 2022

18:30 - 19:00 GMT-4	MHSPC, is there an ideal sequence to start with?	Neal Shore, MD (USA)
19:00 - 19:30 GMT-4	MCRPC best standard of care and new horizons	Alicia Morgans, MD (USA)
19:30 - 20:00 GMT-4	All you need to know about new targeted therapies and PSMA	Michael Morris, MD (USA)
20:00 - 21:00 GMT-4	Clinical case of metastatic disease	